I-Mab Biopharma (IMAB) to Divest Assets and Business Operations in China Feb 7, 2024 06:01AM
I-Mab Signs Agreement to Divest its Assets and Business Operations in China Feb 7, 2024 06:00AM
I-Mab (IMAB) PT Lowered to $25 at Cantor Fitzgerald Aug 30, 2022 02:53PM
Cantor Fitzgerald Reiterates Overweight Rating, $95 Price Target on I-Mab (IMAB), Expects "Greater Appreciation for the Company's Pipeline" Apr 12, 2022 08:16AM
No Fundamental Reason of I-Mab's (IMAB) Weakness, Risk-Reward is to The Upside - Cantor Fitzgerald Jan 24, 2022 06:27AM


Aug 30, 2021 08:00AM I-Mab Announces Upcoming Participation at September Conferences
Jun 9, 2021 04:47PM I-Mab (IMAB) PT Raised to $90 at Cantor Fitzgerald on Pipeline Enhancements
Feb 9, 2021 08:00AM Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
Feb 5, 2021 05:27PM Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
Feb 4, 2021 06:47AM I-Mab (IMAB) PT Raised to $76 at Cantor Fitzgerald
Sep 8, 2020 08:00AM I-Mab Announces Upcoming Participation at September Conferences
Jul 27, 2020 04:57AM UPDATE: Cantor Fitzgerald Starts I-Mab (IMAB) at Overweight